AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma - Leonard, John P.; Trneny, Marek; Izutsu, Koji; Fowler, Nathan H.; Hong, Xiaonan; Zhu, Jun; Zhang, Huilai; Offner, Fritz; Scheliga, Adriana; Nowakowski, Grzegorz S.; Pinto, Antonio; Re, Francesca; et al. (Journal of clinical oncology, 2019)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Female; Humans; Lenalidomide - administration & dosage; Lenalidomide - adverse effects; Lymphoma, B-Cell, Marginal Zone - drug therapy; Lymphoma, Follicular - drug therapy; Male; Middle Aged; Neoplasm Recurrence, Local - drug therapy; ORIGINAL REPORTS; Placebos; Rituximab - adverse effects; Rituximab - therapeutic use